327 related articles for article (PubMed ID: 32943257)
1. Dupilumab therapy for patients with refractory eosinophilic otitis media associated with bronchial asthma.
Iino Y; Sekine Y; Yoshida S; Kikuchi S
Auris Nasus Larynx; 2021 Jun; 48(3):353-360. PubMed ID: 32943257
[TBL] [Abstract][Full Text] [Related]
2. Clinical efficacy of anti-IL-5 monoclonal antibody mepolizumab in the treatment of eosinophilic otitis media.
Iino Y; Takahashi E; Ida S; Kikuchi S
Auris Nasus Larynx; 2019 Apr; 46(2):196-203. PubMed ID: 30122651
[TBL] [Abstract][Full Text] [Related]
3. Dupilumab improves eosinophilic otitis media associated with eosinophilic chronic rhinosinusitis.
Nakashima D; Nakayama T; Minagawa S; Adachi T; Mitsuyama C; Shida Y; Nakajima T; Haruna SI; Matsuwaki Y
Allergol Int; 2023 Oct; 72(4):557-563. PubMed ID: 37061391
[TBL] [Abstract][Full Text] [Related]
4. Cycling therapy with benralizumab and dupilumab for severe eosinophilic asthma with eosinophilic chronic rhinosinusitis and eosinophilic otitis media.
Hamada S; Ogino E; Yasuba H
Allergol Int; 2021 Jul; 70(3):389-391. PubMed ID: 33685801
[No Abstract] [Full Text] [Related]
5. Risk factors associated with severity of eosinophilic otitis media.
Kanazawa H; Yoshida N; Yamamoto H; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Iino Y
Auris Nasus Larynx; 2014 Dec; 41(6):513-7. PubMed ID: 25199747
[TBL] [Abstract][Full Text] [Related]
6. Successful treatment of eosinophilic otitis media associated with severe bronchial asthma with an anti-IL-5 monoclonal antibody, mepolizumab.
Suzaki I; Kimura Y; Tanaka A; Hirano K; Ishibashi A; Mizuyoshi T; Ando I; Kitajima T; Watanabe S; Hinohira Y; Kobayashi H
Auris Nasus Larynx; 2019 Feb; 46(1):141-146. PubMed ID: 29909018
[TBL] [Abstract][Full Text] [Related]
7. IL13 May Play an Important Role in Developing Eosinophilic Chronic Rhinosinusitis and Eosinophilic Otitis Media with Severe Asthma.
Shimizu H; Hayashi M; Kato H; Nakagawa M; Imaizumi K; Okazawa M
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681869
[TBL] [Abstract][Full Text] [Related]
8. New Insights into Eosinophilic Otitis Media.
Kanazawa H; Yoshida N; Iino Y
Curr Allergy Asthma Rep; 2015 Dec; 15(12):76. PubMed ID: 26546407
[TBL] [Abstract][Full Text] [Related]
9. Eosinophilic otitis media; state-of-the-art diagnosis and treatment.
Iino Y
Auris Nasus Larynx; 2023 Aug; 50(4):479-489. PubMed ID: 36528403
[TBL] [Abstract][Full Text] [Related]
10. Complete Remission of Severe Eosinophilic Otitis Media With Dupilumab: A Case Report.
van der Lans RJL; van Spronsen E; Fokkens WJ; Reitsma S
Laryngoscope; 2021 Dec; 131(12):2649-2651. PubMed ID: 34216146
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Bachert C; Han JK; Desrosiers M; Hellings PW; Amin N; Lee SE; Mullol J; Greos LS; Bosso JV; Laidlaw TM; Cervin AU; Maspero JF; Hopkins C; Olze H; Canonica GW; Paggiaro P; Cho SH; Fokkens WJ; Fujieda S; Zhang M; Lu X; Fan C; Draikiwicz S; Kamat SA; Khan A; Pirozzi G; Patel N; Graham NMH; Ruddy M; Staudinger H; Weinreich D; Stahl N; Yancopoulos GD; Mannent LP
Lancet; 2019 Nov; 394(10209):1638-1650. PubMed ID: 31543428
[TBL] [Abstract][Full Text] [Related]
12. Real-life effectiveness of dupilumab in patients with mild to moderate bronchial asthma comorbid with CRSwNP.
Minagawa S; Araya J; Watanabe N; Fujimoto S; Watanabe J; Hara H; Numata T; Kuwano K; Matsuwaki Y
BMC Pulm Med; 2022 Jun; 22(1):258. PubMed ID: 35764984
[TBL] [Abstract][Full Text] [Related]
13. Bone conduction hearing level in patients with eosinophilic otitis media associated with bronchial asthma.
Iino Y; Usubuchi H; Kodama K; Takizawa K; Kanazawa T; Ohta Y
Otol Neurotol; 2008 Oct; 29(7):949-52. PubMed ID: 18758390
[TBL] [Abstract][Full Text] [Related]
14. Clinical efficacy of anti-IgE therapy for eosinophilic otitis media.
Iino Y; Hara M; Hasegawa M; Matsuzawa S; Shinnabe A; Kanazawa H; Yoshida N
Otol Neurotol; 2012 Sep; 33(7):1218-24. PubMed ID: 22825324
[TBL] [Abstract][Full Text] [Related]
15. Periostin in middle ear mucosa according to eosinophilic otitis media severity: Middle ear pathology-based treatment.
Esu Y; Masuda M; Yoshida N
Auris Nasus Larynx; 2020 Aug; 47(4):527-535. PubMed ID: 32586742
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of Biologics on Refractory Eosinophilic Otitis Media Associated with Bronchial Asthma or Severe Uncontrolled CRSwNP.
De Corso E; Montuori C; Settimi S; Mele DA; Cantiani A; Corbò M; Cantone E; Paludetti G; Galli J
J Clin Med; 2022 Feb; 11(4):. PubMed ID: 35207196
[TBL] [Abstract][Full Text] [Related]
17. Efficacy of mepolizumab for patients with severe asthma and eosinophilic chronic rhinosinusitis.
Numata T; Nakayama K; Utsumi H; Kobayashi K; Yanagisawa H; Hashimoto M; Minagawa S; Ishikawa T; Hara H; Araya J; Kuwano K
BMC Pulm Med; 2019 Oct; 19(1):176. PubMed ID: 31606052
[TBL] [Abstract][Full Text] [Related]
18. When sequential use of mepolizumab and dupilumab in a severe atopic eosinophilic asthmatic questions the role of eosinophils in mediating the clinical expression of the disease: a case report.
Sabbe M; Schleich F; Janssens P; Louis R
J Med Case Rep; 2024 Jan; 18(1):63. PubMed ID: 38291489
[TBL] [Abstract][Full Text] [Related]
19. Improvement of Suspected Eosinophilic Otitis Media with Targeted Biologic Therapy.
Ryder CY; Zacharek MA; Welch CM
Otol Neurotol; 2023 Jun; 44(5):462-468. PubMed ID: 37026811
[TBL] [Abstract][Full Text] [Related]
20. Eosinophilic inflammation in the middle ear induces deterioration of bone-conduction hearing level in patients with eosinophilic otitis media.
Iino Y; Usubuchi H; Kodama K; Kanazawa H; Takizawa K; Kanazawa T; Ohta Y
Otol Neurotol; 2010 Jan; 31(1):100-4. PubMed ID: 19816234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
